Osteoarthritis year 2012 in review: Clinical

Osteoarthritis and Cartilage

Volumn 20, Issue 12, 2012, Pages 1465-1469

  Hochberg, M C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Obesity; Osteoarthritis; Risk factors; Treatment

Indexed keywords

ADALIMUMAB; CELECOXIB; CHONDROITIN SULFATE; DULOXETINE; GLUCOSAMINE SULFATE; HYALURONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; TANEZUMAB;

ALTERNATIVE MEDICINE; BODY MASS; DRUG EFFICACY; FOLLOW UP; GENOMICS; HIP; HUMAN; KNEE; KNEE PAIN; MEDLINE; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

BIOMEDICAL RESEARCH; DISEASE MANAGEMENT; HUMANS; OSTEOARTHRITIS;

EID: 84867847575     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2012.07.022     Document Type: Review

References (40)

1. Helmick C.G., Felson D.T., Lawrence R.C., Gabriel S., Hirsch R., Kwoh C.K., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum 2008, 58:26-35.
2. Lane N.E., Brandt K., Hawker G., Peeva E., Schreyer E., Tsuji W., et al. OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthritis Cartilage 2011, 19:478-482.
3. Losina E., Walensky R.P., Reichmann W.M., Holt H.L., Gerlovin H., Solomon D.H., et al. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med 2011, 154:217-226.
4. Nuesch E., Dieppe P., Reichenbach S., Williams S., Iff S., Juni P. All cause and disease specific mortality in patients with knee osteoarthritis: population based cohort study. BMJ 2011, 342:d1165.
5. Hochberg M.C., Altman R.D., April K.T., Benkhalti M., Guyatt G., McGowan J., et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012, 64:455-474.
6. Haugen I.K., Englund M., Aliabadi P., Niu J., Clancy M., Kvien T.K., et al. Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Study. Ann Rheum Dis 2011, 70:1581-1586.
7. Pereira D., Peleteiro B., Araujo J., Branco J., Santos R.A., Ramos E. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage 2011, 19:1270-1285.
8. Acheson R.M., Collart A.B., Greenberg R.H., Clemett A.R. New Haven survey of joint disease: photographs and other variables in screening for arthritis of the hands. Am J Epidemiol 1969, 90:224-235.
9. Hirsch R., Guralnik J.M., Ling S.M., Fried L.P., Hochberg M.C. The patterns and prevalence of hand osteoarthritis in a population of disabled older women: the Women's Health and Aging Study. Osteoarthritis Cartilage 2000, 8(Suppl A):S16-S21.
10. Jonsson H., Helgadottir G.P., Aspelund T., Sverrisdottir J.E., Eiriksdottir G., Sigurdsson S., et al. The use of digital photographs for the diagnosis of hand osteoarthritis: the AGES-Reykjavik study. BMC Musculoskelet Disord 2012, 13:20.
11. Nguyen U.S., Zhang Y., Zhu Y., Niu J., Zhang B., Felson D.T. Increasing prevalence of knee pain and symptomatic knee osteoarthritis: survey and cohort data. Ann Intern Med 2011, 155:725-732.
12. Muthuri S.G., McWilliams D.F., Doherty M., Zhang W. History of knee injuries and knee osteoarthritis: a meta-analysis of observational studies. Osteoarthritis Cartilage 2011, 19:1286-1293.
13. Lubar D., White P.H., Callahan L.F., Chang R.W., Helmick C.G., Lappin D.R., et al. A national public health agenda for osteoarthritis 2010. Semin Arthritis Rheum 2010, 39:323-326.
14. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
15. Conaghan P.G., Dickson J., Grant R.L. Care and management of osteoarthritis in adults: summary of NICE guidance. BMJ 2008, 336:502-503. for the Guideline Development Group.
16. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
17. Bliddal H., Leeds A.R., Stigsgaard L., Astrup A., Christensen R. Weight loss as treatment for knee osteoarthritis symptoms in obese patients: 1-year results from a randomized controlled trial. Ann Rheum Dis 2011, 70:1798-1803.
18. Gill R.S., Al-Adra D.P., Shi X., Sharma A.M., Birch D.W., Karmali S. The benefits of bariatric surgery in obese patients with hip and knee osteoarthritis: a systematic review. Obes Rev 2011, 12:1083-1089.
19. Pinto D., Robertson M.C., Hansen P., Abbott J.H. Cost-effectiveness of nonpharmacologic, nonsurgical interventions for hip and/or knee osteoarthritis: systematic review. Value Health 2012, 15:1-12.
20. Lapane K.L., Sands M.R., Yang S., McAlindon T.E., Eaton C.B. Use of complementary and alternative medicine among patients with radiographically-confirmed knee osteoarthritis. Osteoarthritis Cartilage 2012, 20:22-28.
21. Wandel S., Juni P., Tendal B., Nuesch E., Villiger P.M., Welton N.J., et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010, 341:c4675.
22. Gabay C., Medinger-Sadowski C., Gascon D., Kolo F., Finckh A. Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum 2011, 63:3383-3391.
23. Strand V., Simon L.S., Dougados M., Sands G.H., Bhadra P., Breazna A., et al. Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol 2011, 38:2625-2634.
24. Roth S.H., Fuller P. Diclofenac sodium topical solution 1.5% w/w with dimethyl sulfoxide compared with placebo for the treatment of osteoarthritis: pooled safety results. Postgrad Med 2011, 123:180-188.
25. Altman R.D., Rosen J.E., Bloch D.A., Hatoum H.T. Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the Open-label Extension Study of the FLEXX Trial. Osteoarthritis Cartilage 2011, 19:1169-1175.
26. Conrozier T., Bailblanc J.C., Richette P., Mulleman D., Maillet B., Henrotin Y., et al. Early effect of hyaluronic acid intra-articular injections on serum and urine biomarkers in patients with knee osteoarthritis: an open-label observational prospective study. J Orthop Res 2012, 30:679-685.
27. Foti C., Cisari C., Carda S., Giordan N., Rocco A., Frizziero A., et al. A prospective observational study of the clinical efficacy and safety of intra-articular sodium hyaluronate in synovial joints with osteoarthritis. Eur J Phys Rehabil Med 2011, 47:407-415.
28. Pavelka K., Uebelhart D. Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial) vs hylan GF-20 (Synvisc) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study. Osteoarthritis Cartilage 2011, 19:1294-1300.
29. Rat A.C., Baumann C., Guillemin F. National, multicenter, prospective study of quality of life in patients with osteoarthritis of the knee treated with hylan GF-20. Clin Rheumatol 2011, 30:1285-1293.
30. Merolla G., Sperling J.W., Paladini P., Porcellini G. Efficacy of Hylan GF-20 versus 6-methylprednisolone acetate in painful shoulder osteoarthritis: a retrospective controlled trial. Musculoskelet Surg 2011, 95:215-224.
31. Munteanu S.E., Zammit G.V., Menz H.B., Landorf K.B., Handley C.J., Elzarka A., et al. Effectiveness of intra-articular hyaluronan (Synvisc, hylan GF-20) for the treatment of first metatarsophalangeal joint osteoarthritis: a randomized placebo-controlled trial. Ann Rheum Dis 2011, 70:1838-1841.
32. Alberto M., Umberto M., Emanuele B., Bruno L., Valentina G., Prisco P., et al. Intra-articular injection of hyaluronic acid (MS 1,500-2,000 kDa; HyalOne) in symptomatic osteoarthritis of the hip: a prospective cohort study. Arch Orthop Trauma Surg 2011, 131:1677-1685.
33. Huang T.L., Chang C.C., Lee C.H., Chen S.C., Lai C.H., Tsai C.L. Intra-articular injections of sodium hyaluronate (Hyalgan) in osteoarthritis of the knee: a randomized, controlled, double-blind, multicenter trial in the Asian population. BMC Musculoskelet Disord 2011, 12:221.
34. McNeil J.D. Intra-articular hyaluronic acid preparations for use in the treatment of osteoarthritis. Int J Evid Based Healthc 2011, 9:261-264.
35. Frakes E.P., Risser R.C., Ball T.D., Hochberg M.C., Wohlreich M.M. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011, 27:2361-2372.
36. Nagashima H., Suzuki M., Araki S., Yamabe T., Muto C. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage 2011, 19:1405-1412. for the Tanezumab Investigators.
37. Verbruggen G., Wittoek R., Cruyssen B.V., Elewaut D. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomized trial on structure modification. Ann Rheum Dis 2011, 10.1136/ard.2011.149849.
38. Matthews G.L., Hunter D.J. Emerging drugs for osteoarthritis. Expert Opin Emerg Drugs 2011, 16:479-491.
39. Proceedings from the HSS Osteoarthritis Summit: Frontiers in Osteoarthritis Research, Prevention and Care. HSSJ 2012, vol. 8:1-83. C.N. Cornell (Ed.).
40. Robbins L., Kulesa M.G. The state of the science in the prevention and management of osteoarthritis. Am J Nurs 2012, 112:25-33.